- $271.51m
- $220.51m
- $212.45m
- 75
- 26
- 67
- 56
Annual income statement for LifeMD, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 37.3 | 92.9 | 119 | 153 | 212 |
| Cost of Revenue | |||||
| Gross Profit | 28.4 | 74.9 | 100 | 134 | 188 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 96 | 151 | 162 | 167 | 229 |
| Operating Profit | -58.7 | -58.3 | -43.4 | -14.8 | -16.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -60.4 | -61.3 | -44.7 | -17.4 | -18.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -60.5 | -61.3 | -45 | -17.8 | -18.7 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -58.6 | -60.9 | -45.5 | -20.6 | -18.9 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -63.4 | -61.8 | -48.6 | -23.7 | -22 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -4.4 | -2.19 | -1.39 | -0.693 | -0.534 |